SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE CRYPTO is gaining traction with its new listing on MEXC Meme+, energizing its dedicated "Grok's AI dog" community who are actively discussing its strong fundamentals and unique origin story as a leading AI meme coin.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy crypto is trending amidst strong community skepticism, as many investors who experienced significant losses with the original Mullen Automotive stock now view the new token on the Solana network as another potential 'scam,' while a smaller group of 'Mullenaires' actively promotes it.

SharonAI Holdings, Inc. is a technology company. It focuses on high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI Holdings (SHAZ) is surging amidst community discussion following the release of an ambitious long-term roadmap outlining significant capacity expansion into 2028, further fueled by its association with the bullish AI sector and a notable photo of its co-founder with NVIDIA's CEO.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is actively discussed as its acquisition of Astria Therapeutics completes, integrating the late-stage HAE therapy navenibart into its pipeline just before upcoming earnings and new clinical data presentations. Community sentiment is mixed, balancing optimism for the strengthened rare disease portfolio against concerns over stock performance, perceived dilution, and significant short interest.

Cogent Communications Holdings, Inc. engages in the provision of Internet access and Internet Protocol (IP) communications solutions. It offers Internet access and data transport through its fiber optic, IP data-only network, ethernet transport, and colocation services. The company was founded by David Schaeffer in August 1999 and is headquartered in Washington, DC.

Cogent Communications Holdings Inc

Cogent Communications is trending after a substantial dividend cut and widespread community frustration regarding management's communication on its highly leveraged balance sheet, exacerbated by recent CEO share sales; however, some investors are eyeing a potential turnaround driven by growth in AI wavelength revenue and anticipated data center asset divestitures.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending amid resurfacing acquisition rumors, with French publication La Lettre reporting a potential $176-per-share offer from AstraZeneca following earlier Eli Lilly bid speculation. The community is actively discussing the differentiated profile of obefazimod for inflammatory bowel disease and the high buyout premium the company could command.

MKS, Inc. provides instruments, systems, subsystems and process control solutions to measure, control, power, monitor, and analyze parameters of manufacturing processes to improve process performance and productivity for its customers. It operates through the following segments: VSD (Vacuum Solutions Division), PSD (Photonics Solutions Division), and MSD (Materials Solutions Division). The VSD segment delivers foundational technology solutions to semiconductor manufacturing, electronics and packaging and specialty industrial applications. The PSD Segment provides a range of instruments, components and subsystems to edge semiconductor manufacturing, electronics and packaging and specialty industrial applications. The MSD segment develops process and manufacturing technologies for advanced surface modification, electroless and electrolytic plating, and surface finishing. The company was founded in 1961 and is headquartered in Andover, MA.

MKS Inc.

MKS Instruments, Inc.

MKS Instruments is trending as investors digest a mixed earnings report, where an EPS miss was overshadowed by strong revenue growth and optimistic guidance, reinforcing its position as a key enabler in the expanding AI and semiconductor capital equipment sector. The community is actively discussing its significant role in data center buildout and next-generation manufacturing, viewing it as an attractive long-term play despite some technical signals suggesting caution and recent convertible note offerings.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies (EMAT) is trending with significant volatility and trading halts, fueled by its extremely low public float and widespread community discussion around its potential to secure a US-based critical minerals supply chain. Investors are actively debating short-term "pump and dump" risks versus a long-term opportunity, as the company aims to reduce reliance on China for rare earth materials.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following robust Phase 2 axSpA clinical trial results for sonelokimab, described by the community as potentially "best-in-class" and generating significant buzz ahead of its Investor Day, amplifying discussions around substantial short interest and potential major acquisition interest.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

Anticipation is building for OPGN's shareholder meeting, where a name change to CapForce and critical resolutions for a potential Nasdaq relisting are expected to pass, signaling its transformation into an AI-enabled fintech platform. This pivot from a struggling biotech, backed by major capital and connections to a $1B+ unicorn, fuels strong community speculation about explosive growth despite historical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company increased its quarterly dividend by more than 8% to $0.26 per share.</li><li>Revenue during Q4 came in at $5.42 billion, that was also below the consensus estimate of $5.91 billion.</li><li>As of December 31, 2025, Occidental’s worldwide proved reserves totaled 4.6 billion barrels of oil equivalent (BOE).</li></ul>Occidental Petroleum (<a href="https://stocktwits.com/symbol/SEDG">OXY</a>) shares rose in extended hours of trading on Wednesday despite missing analysts’ estimates for revenue but showed strength in its operations and also raised its dividend.&nbsp;The company reported adjusted earnings of $0.31 per share for the fourth quarter of 2025, beating analysts’ estimates of $0.18 per share, as per data from fiscal.ai. Revenue came in at $5.42 billion, that was below the consensus estimate of $5.62 billion.The company increased its quarterly dividend by more than 8% to $0.26 per share. The dividend will be payable on April 15, 2026, to stockholders of record as of March 10, 2026.&nbsp;<h2 class="st-heading-2">Strength In Operations</h2>The oil firm said that its strong operational performance drove operating cash flow of $2.6 billion and operating cash flow before working capital of $2.7 billion during the quarter.&nbsp;It strengthened its balance sheet with the completion of the OxyChem sale on January 2, 2026, reducing debt by $5.8 billion since mid-December 2025 and bringing principal debt to date to $15.0 billion.Occidental’s total production reached 1,481 thousand barrels of oil equivalent per day (Mboed), exceeding the high end of its guidance.“Our emphasis on operational excellence and cost efficiency drove meaningful production and operating expense outperformance during the fourth quarter,” said President and Chief Executive Officer Vicki Hollub.<h2 class="st-heading-2">Oil Reserves</h2>As of December 31, 2025, Occidental’s worldwide proved reserves totaled 4.6 billion barrels of oil equivalent (BOE).The 2025 All-In Reserves Replacement Ratio was 98%, with a three-year average of 154%. The 2025 Organic Reserves Replacement Ratio was 107%, with a three-year average of 116%, the company said.&nbsp;<h2 class="st-heading-2">How Did Stocktwits’ Users React?</h2>Retail sentiment around OXY trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;One bullish user predicted the stock to cross the $50 mark on Thursday.<a href="https://stocktwits.com/Aombeus/message/645274246">https://stocktwits.com/Aombeus/message/645274246</a>Shares in the company have fallen 0.7% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Occidental Petroleum Corporation (OXY) logo and models of an oil rig and oil barrels are pictured in this illustration photo taken in Kyiv on 19 August, 2021. 

OXY Stock Is Rising After-Hours – What Is The Reason?

 OXY strengthened its balance sheet with the completion of the OxyChem sale on January 2, 2026, reducing debt by $5.8 billion since mid-December 2025. 

Equity

 OXY strengthened its balance sheet with the completion of the OxyChem sale on January 2, 2026, reducing debt by $5.8 billion since mid-December 2025. 


Defensive ETFs Beyond Gold: Where to Invest When Metals Cool 

With gold and silver prices tumbling, discover defensive ETFs that help cushion portfolios beyond metals.

Should Vanguard Value ETF (VTV) Be on Your Investing Radar?

See Which Of The Latest 13F Filers Holds VTV

At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2025 reporting period, and noticed that Vanguard Index Funds - Vanguard Value ETF (Symbol: VTV...

With Markets on Edge, Defensive ETFs Deserve a Second Look

Rising geopolitical risks, Fed uncertainty and credit card policy debates make defensive ETFs worth a look.

Is it Time to Pay Attention to Value ETF Investing Again?

As geopolitical risks rise and volatility lingers, value investing stands out as an attractive strategy. Look at ETFs to simplify the implementation of the strategy.

VTV vs. SPTM: Should Investors choose Vanguard's Value ETF or the S&P 1500's Stability?

Key PointsVanguard Value ETF carries a higher yield but slightly higher expenses than SPTM...

Vanguard Growth ETF vs. Vanguard Value ETF: Which ETF Will Outperform in 2026?

Key PointsGrowth stocks are set to outperform value stocks once again in 2025...

ETFs to Keep Your Portfolio on Track in the Long Term

Despite November's volatility, optimism is returning to Wall Street. Discover how long-term strategies combined with ETFs can help investors build resilient portfolios ready to capture the next phase of the bull market.

Stay Ahead of Market Turmoil With These ETFs

With stocks sliding, volatility spiking and bubble concerns mounting, investors need a defensive game plan. These ETFs can help you navigate the turbulence.

VTV
Vanguard Value ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VTV News

VTVVanguard Value ETF